ASX ANNOUNCEMENT

5 November 2026

Pathkey investor webinar recording now available

Pathkey.AI Ltd (ASX: PKY) (Pathkey or the Company) is pleased to advise shareholders that a recording of its latest investor webinar is now available.

Group CEO Andrew Farnsworth and Director Damon Rasheed, who leads TrialKey, present an update on the Company's two AI businesses, the capabilities demonstrated to date and the priorities for commercialisation.

Watch the Pathkey investor webinar recording

https://www.pathkey.ai/media/videos/261105-Pathkey.AI-Investor-Webinar.mp4

The presentation and Q&A cover:

- Chipforge's demonstrated capability: how the platform brings chip design, testing and verification together, including an independent expert taking written requirements through to working programmable hardware without assistance from the Chipforge team.
- The commercial opportunity: the engineering capacity constraints Chipforge seeks to address, customer opportunities across Asia Pacific and the intended progression from fixed-price proof-of-value projects to repeat work, usage fees and software licences.
- Product development priorities: the targeted January to March 2027 release of Chipforge Studio, broader support for chip-design tools and longer-term development of custom silicon and secure customer deployment options.
- TrialKey's clinical trial offering: how machine learning and its AI agent evaluate alternative study designs within budget, clinical and regulatory constraints, with the aim of improving trial design before significant expenditure is committed.
- Customer engagement and next steps: management discusses how demonstrated platform capabilities are shaping customer conversations and the opportunity to build longer-term relationships across both businesses.

Product development dates are targets and remain subject to technical progress and available resources. Further customer work and recurring revenue depend on successful delivery, customer adoption and commercial agreements.

This announcement has been authorised for release by the Board of Pathkey.AI Ltd.

ENDS

For further information please contact: investors@pathkey.ai

About Pathkey AI

Pathkey.AI Ltd (ASX: PKY) is an Australian technology company focused on developing proprietary AI powered large language model solutions for data intensive industries. TrialKey is focused on clinical trial design and optimisation. Chipforge is developing an AI-powered chip design platform for semiconductor engineering. Both TrialKey and Chipforge platforms are built around an agent-based AI architecture combining large-language-model functionality with neuro-symbolic reasoning to solve complex design optimisation problems. In each platform, AI agents generate candidate solutions, evaluate them against defined objectives and iteratively refine them through a structure reflection look using reinforcement driven optimisation.